Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard

robot
Abstract generation in progress

Skye Bioscience (SKYE) received a Nasdaq deficiency letter on March 17, 2026, for failing to maintain the minimum $1.00 bid price for 30 consecutive business days. The company has 180 days, until September 14, 2026, to regain compliance, with a reverse stock split as an option. SKYE’s stock continues to trade on the Nasdaq Global Market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin